Effects of Simvastatin on Apolipoprotein M
Author Information
Author(s): Zhang Xiaoying, Mao Shubing, Luo Guanghua, Wei Jiang, Berggren-Söderlund Maria, Nilsson-Ehle Peter, Xu Ning
Primary Institution: Comprehensive Laboratory, Third Affiliated Hospital of Suzhou University, Changzhou, China
Hypothesis
Does simvastatin affect apolipoprotein M expression in hyperlipidemic mice and HepG2 cells?
Conclusion
Simvastatin had no effect on apoM levels in hyperlipidemic mice but inhibited apoM expression in HepG2 cells.
Supporting Evidence
- Simvastatin treatment did not influence serum apoM levels in hyperlipidemic mice.
- ApoM serum levels were significantly correlated to the age of the mice.
- In HepG2 cell cultures, simvastatin significantly decreased apoM mRNA levels.
Takeaway
This study looked at how a cholesterol-lowering medicine called simvastatin affects a protein called apoM in mice and cells. It found that while simvastatin didn't change apoM levels in mice, it did lower apoM levels in cell cultures.
Methodology
The study used male Swiss mice and HepG2 cells to assess the effects of simvastatin on apoM levels through various treatments and measurements.
Limitations
The study did not explore the underlying mechanisms for the differences observed between in vivo and in vitro results.
Participant Demographics
Male Swiss mice, 12 weeks old, weighing 30-32 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website